HALEON PLC
LSE:HLN

Watchlist Manager
HALEON PLC Logo
HALEON PLC
LSE:HLN
Watchlist
Price: 382.4 GBX 0.47%
Market Cap: 34.6B GBX
Have any thoughts about
HALEON PLC?
Write Note

HALEON PLC
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

HALEON PLC
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
HALEON PLC
LSE:HLN
Other Equity
ÂŁ765m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Unilever PLC
LSE:ULVR
Other Equity
-€2.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PZ Cussons PLC
LSE:PZC
Other Equity
-ÂŁ160m
CAGR 3-Years
-22%
CAGR 5-Years
-13%
CAGR 10-Years
-60%
Science in Sport PLC
LSE:SIS
Other Equity
-ÂŁ290k
CAGR 3-Years
-6%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Warpaint London PLC
LSE:W7L
Other Equity
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Venture Life Group PLC
LSE:VLG
Other Equity
ÂŁ622k
CAGR 3-Years
44%
CAGR 5-Years
20%
CAGR 10-Years
N/A
No Stocks Found

HALEON PLC
Glance View

Market Cap
34.9B GBX
Industry
Consumer products

In the bustling world of consumer healthcare, HALEON PLC stands as a luminary figure, emerging with a focused mission: to deliver everyday health with humanity. Spun off from the pharmaceutical giant GlaxoSmithKline, HALEON now charts its independent course, concentrating on the development and distribution of over-the-counter medications, oral health products, and nutritional supplements. Its diverse portfolio includes household names such as Sensodyne, Panadol, and Centrum, demonstrating its wide-reaching impact on consumers’ health routines. These brands are not merely market fixtures; they represent HALEON’s commitment to blending scientific innovation with consumer insights, aiming to enhance well-being across the globe. HALEON’s business model is poised at the intersection of healthcare and retail, thriving through an intricate blend of strategic marketing, global distribution networks, and strong brand equity. By leveraging extensive consumer research data, HALEON aligns its product offerings with the evolving needs and preferences of its audience. The company generates revenue primarily through product sales, employing an omnichannel strategy that ensures product availability across various retail and digital platforms. Its strategic alliances and network with pharmacies, supermarkets, and online marketplaces cement its accessibility and prominence in the market. Additionally, HALEON's stream of revenue is bolstered by its investment in innovation—a key driver that keeps its product lines relevant and competitive in a dynamic healthcare landscape.

HLN Intrinsic Value
334.53 GBX
Overvaluation 13%
Intrinsic Value
Price

See Also

What is HALEON PLC's Other Equity?
Other Equity
765m GBP

Based on the financial report for Dec 31, 2023, HALEON PLC's Other Equity amounts to 765m GBP.

What is HALEON PLC's Other Equity growth rate?
Other Equity CAGR 1Y
-27%

Over the last year, the Other Equity growth was -27%.

Back to Top